Lonza and Agilent Collaborate on New Analytical Technologies and Tools
Incorporation of Agilent’s analytical technologies into Lonza’s Cocoon® platform will improve quality and consistency, leading to increased access to personalized medicines, according to officials at both companies. Collaboration aims to develop and integrate current and new analytical technologies into patient-scale cell therapy manufacturing workflows with the Cocoon Platform. The companies also aim to define the ideal Critical Quality Attributes required for cell therapies.